177Lu rhPSMA-10.1 + degarelix

177Lu rhPSMA-10.1 + degarelix is a combination therapy for advanced prostate cancer. It combines two distinct treatment approaches: 1. **177Lu rhPSMA-10.1**: A radiopharmaceutical that likely targets prostate-specific membrane antigen (PSMA) using lutetium-177 as the radioactive component. The rhPSMA-10.1 molecule serves as a targeting ligand that binds to PSMA expressed on prostate cancer cells, delivering targeted radiation therapy. 2. **Degarelix (Firmagon)**: A gonadotropin-releasing hormone (GnRH) antagonist that works by directly blocking GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to rapid testosterone suppression without the initial surge seen with GnRH agonists, making it effective for hormone-dependent prostate cancer. The combination likely aims to provide both targeted radiation therapy to cancer cells while simultaneously suppressing testosterone production to inhibit hormone-dependent tumor growth.